Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

NCT06410651 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Nimotuzumab
Chemoradiotherapy
Chemotherapy
Immunotherapy

Interventions

COMBINATION_PRODUCT: Nimotuzumab with chemoradiotherapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences